The content on this site is intended for healthcare professionals only
Dr Delia Guaqueta speaks to ecancer about the role of CDK4/6 inhibitors in the treatment of metastatic breast cancer.
She discusses the data from different trials investigating CDK4/6 inhibitors in the treatment of metastatic breast cancer.
Dr Guaqueta talks about drug approvals and concludes by talking about ecancer.
She says ecancer provides a great opportunity to reach all kinds of physicians and physicians in training and provides an international platform to discuss experiences in treating cancer.
Burden and trends of breast cancer worldwide: Opportunities for prevention?
Patients with early-stage, HR+/HER2-negative BC may benefit from adjuvant T-AC therapy more than from TC
One-year mortality in older adults with breast cancer: prediction using different geriatric tools
Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients
Durable responses in aRCC, how do we optimise treatment?
ASCO 2024: Two studies report on isatuximab combos in transplant-ineligible patients with newly diagnosed multiple myeloma
Comment: EBCC 2024 highlights
Saruparib shows encouraging efficacy and safety in mutant advanced solid tumours
EAU 2024: Bladder cancer latest
